Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?
Steven T. Bird(United States Food and Drug Administration), Abraham G. Hartzema(University of Florida), James M. Brophy(McGill University Health Centre), Joseph A. Delaney(Center for Drug Evaluation and Research), Mahyar Etminan(Oncolytics Biotech (Canada))
Cited by 20
Related Papers
Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data
|BMJ|2017|525
Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis
|Canadian Medical Association Journal|2012|120
Isotretinoin and Risk for Inflammatory Bowel Disease
|JAMA Dermatology|2013|93
Risk of acute kidney injury associated with the use of fluoroquinolones
|Canadian Medical Association Journal|2013|89
Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis
|Clinical Microbiology and Infection|2022|89